Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells $1,206,004.59 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) CEO Christopher Peetz sold 27,279 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $44.21, for a total transaction of $1,206,004.59. Following the completion of the transaction, the chief executive officer now owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 3rd, Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $48.22, for a total transaction of $438,898.44.
• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total transaction of $320,678.98.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ:MIRM traded down $0.85 during trading on Friday, reaching $47.02. The stock had a trading volume of 896,068 shares, compared to its average volume of 512,980. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $54.23. The firm has a market capitalization of $2.30 billion, a price-to-earnings ratio of -23.28 and a beta of 1.04. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The stock has a fifty day simple moving average of $47.89 and a two-hundred day simple moving average of $43.70.

Remove Ads

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. As a group, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in Mirum Pharmaceuticals in the 4th quarter valued at $42,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Mirum Pharmaceuticals by 16.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 73,888 shares of the company's stock valued at $3,055,000 after buying an additional 10,427 shares during the period. Woodline Partners LP increased its holdings in Mirum Pharmaceuticals by 22.2% in the 4th quarter. Woodline Partners LP now owns 404,404 shares of the company's stock valued at $16,722,000 after buying an additional 73,399 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $897,000. Finally, Tema Etfs LLC acquired a new stake in shares of Mirum Pharmaceuticals in the 4th quarter valued at $1,735,000.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on MIRM shares. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright raised their target price on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $58.20.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.